Anlon Healthcare Limited (AHCL)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 16 July 2026

₹15.18

🎯 Key Takeaways

Anlon Healthcare Limited is undergoing a strategic transformation from a struggling specialty chemical player to a scaled CDMO and specialty ingredients manufacturer with clear multi-year growth targets. The company has shifted focus to capacity expansion, regulatory approvals, and backward integration following acquisitions, targeting 30% revenue CAGR over three years.
⚠️ Execution risk around regulatory approvals for key products like Ketoprofen, now delayed to Q3/Q4 FY27, which could impact revenue visibility.

Market Cap

₹710

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About AHCL 📊 Interactive Charts

📖 The Story

Anlon Healthcare Limited is undergoing a strategic transformation from a struggling specialty chemical player to a scaled CDMO and specialty ingredients manufacturer with clear multi-year growth targets. The company has shifted focus to capacity expansion, regulatory approvals, and backward integration following acquisitions, targeting 30% revenue CAGR over three years. Despite a severe near-term earnings dip in Q1 FY26 due to inventory buildup and revenue decline, management remains confident in long-term margin stability and cash flow generation from FY27 onward.

📰 What's Happening

Management announced the incorporation of two new subsidiaries — Anlon Medicare Private Limited for surgical implants and Anlon Biologics Private Limited for biologics — and renamed Remember India Health Links to Anlon Medicos, pending MCA approval. These moves signal a strategic pivot into high-value therapeutic segments. Additionally, the company disclosed its FY27 revenue guidance of INR 600-700 crore and FY28 of INR 800 crore, supported by capacity expansion to 1,400-1,600 MT/year, a INR 130 crore capex plan (50-60% debt-financed), and commercialization of CDMO products by Q3 FY27. The order book stands at INR 280-300 crore consolidated with INR 80-90 crore additional visibility, underpinning growth expectations.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY26
Revenue	51
Operating Profit	15
OPM %	30.1%
Net Profit	11
EPS	₹2.33

The company's financial trajectory shows a sharp near-term contraction followed by a structural inflection. Q1 FY26 revenue collapsed 69.9% YoY to ₹3,330.89 lakhs with net profit down 78.6%, driven by a 537.19 lakh inventory increase and weak demand. However, this appears to be a transitional trough, as evidenced by FY26 revenue growth of 158.5% to ₹172.22 crore and EBITDA margin expansion to 27.74% from prior periods. The sequential improvement in operational metrics, coupled with management's FY27-FY28 revenue targets, suggests the current downturn is being managed through strategic reinvestment rather than fundamental deterioration.

🔮 Management Outlook & What's Next

Management has provided detailed forward guidance through regulatory filings, projecting INR 600-700 crore revenue for FY27 and INR 800 crore for FY28, underpinned by capacity expansion and CDMO commercialization. Key milestones include Dexketoprofen EDQM approval within 2-3 months, Ketoprofen filing delayed to Q3/Q4 FY27, and receivables days reduction to 180 days by FY27. Capex of INR 130 crore is planned with 50-60% debt financing, avoiding equity dilution. Inventory is expected to decline 20-25% in Q2 FY27, and EBITDA margin is targeted at 25% long-term despite raw material inflation. These disclosures reflect a structured, capital-light growth strategy with clear inflection points tied to regulatory and commercial execution.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	2025-2026
Equity Capital	53
Reserves	177
Borrowings	44
Total Liabilities	119
Fixed Assets	58
Investments	0
Total Assets	374

The balance sheet shows a strengthening financial position with equity of ₹53 crore and reserves of ₹177 crore, while borrowings stand at ₹44 crore. Total assets have grown to ₹374 crore, indicating asset base expansion aligned with capex plans. The planned INR 130 crore capex, partially debt-financed, is sustainable given internal cash flow expectations of INR 65-70 crore in FY27 and improving working capital management. Receivables are targeted to reduce from 130-140 days to 180 days by FY27, enhancing cash conversion. The debt financing approach and focus on internal accruals suggest disciplined capital allocation without dilutive equity raises.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM CIPLA DRREDDY

⚠️ Risk Factors

1. Execution risk around regulatory approvals for key products like Ketoprofen, now delayed to Q3/Q4 FY27, which could impact revenue visibility. 2. Margin pressure from raw material inflation, despite a long-term EBITDA target of 25%, requires effective cost pass-through amid competitive market dynamics. 3. Integration risks from recent acquisitions of Bizotic Lifescience and Apiqo Organics, and new subsidiary setups, which may strain cash flows if commercialization timelines slip. 4. Inventory management remains critical — a 537.19 lakh increase in Q1 FY26 highlights vulnerability to overstocking in transitional phases.

📋 Recent Filings

🧠 Analyst's Read

Anlon Healthcare is transitioning from a high-growth but unprofitable phase to a structured scale-up with clear milestones in CDMO commercialization and capacity utilization. The near-term earnings volatility is expected, but the long-term narrative hinges on execution of regulatory filings, timely capacity ramp-up, and working capital normalization. Investors should monitor Dexketoprofen approval timelines, inventory correction pace in Q2 FY27, and progress toward the 180-day receivables target as early indicators of operational momentum.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on AHCL

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-16.

📡 Get AI alerts when AHCL files new disclosures

Track AHCL filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track AHCL — Free

Free account · 2 AI queries/day